New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareIpamorelin vs Cardiogen

Ipamorelin vs Cardiogen

Side-by-side comparison of key properties, dosing, and research.

Growth Hormone Peptides
Ipamorelin
Anti-Aging & Longevity
Cardiogen
Summary
Ipamorelin is a selective GHRP (growth hormone releasing peptide) and one of the cleanest GH secretagogues available. It selectively stimulates GH release without significantly raising cortisol, prolactin, or appetite — making it ideal for long-term use and anti-aging protocols.
Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
Half-Life
2 hours
Short (minutes); gene-regulatory effects persist longer
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
100–300 mcg
10 mg per day
Frequency
Once to twice daily
Daily for 10–30 days
Key Benefits
  • Increases lean muscle mass
  • Enhances fat loss
  • Improves recovery time
  • Strengthens bones and joints
  • Better sleep quality and REM sleep
  • Enhanced skin elasticity
  • Minimal impact on hunger or cortisol
  • No cortisol or prolactin spike
  • Clean GH release suitable for long-term protocols
  • Cardioprotective effects on myocardial tissue
  • Normalization of cardiomyocyte protein synthesis
  • May improve cardiac rhythm and conduction
  • Support for recovery from ischemic cardiac events
  • Anti-aging effects on heart tissue
  • Potential reduction in cardiac fibrosis
  • Often combined with Epithalon for comprehensive cardiovascular longevity support
Side Effects
  • Injection site irritation
  • Temporary water retention (mild)
  • Possible hunger increase (milder than GHRP-6)
  • Numbness or tingling in extremities (rare)
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse cardiovascular events reported at standard doses
Stacks With